We are thrilled to announce that MILabs has successfully raised $20 million in our latest funding round, a testament to the trust and belief investors have in our mission and innovative technology. Specializing in high-performance standalone and integrated imaging systems, such as SPECT, PET, CT, and Optical Imaging, MILabs focuses on advancing molecular and in vivo imaging research. Our state-of-the-art 4x4D multimodal imaging technology delivers unparalleled four-dimensional imaging capabilities, enabling researchers to access complementary, data-rich, co-registered images that were previously impossible to obtain with individual systems. This round of funding will be pivotal in enhancing our capacity for continuous innovation, allowing us to further refine and develop our technologies that support researchers in tackling complex diseases, including cancer, diabetes, neurodegenerative disorders, and cardiac diseases.
With over 300 imaging modules installed globally, MILabs collaborates with leading universities, hospitals, contract research organizations, and pharmaceutical companies, significantly contributing to the advancement of new diagnostic solutions and therapies. This capital will not only bolster our R&D efforts but will also expand our supportive services to ensure our partners gain maximum value from our cutting-edge imaging systems. As we move forward, we remain dedicated to our vision of "providing small details for big discoveries," making molecular imaging clearer and more accessible. Stay tuned for exciting developments as we leverage this funding to push the boundaries of science and deliver innovative solutions to accelerate research discoveries. To learn more about how our imaging technologies are shaping the future, visit us at www.milabs.com.
